Drawing for SIGRID THERAPEUTICS

USPTO serial 88873084

SIGRID THERAPEUTICS

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
CLARK, ANDREW T
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SIGRID THERAPEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Bradley L. Cohn

Bradley L. Cohn PATTISHALL, MCAULIFFE, NEWBURY, HILLIARD & GERALDS200 S. WACKER DRIVE, SUITE 2900CHICAGO, IL 60606UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Dietetic preparations adapted for medical use; dietetic substances in the nature of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions adapted for medical use; pharmaceuticals and natural remedies for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; preparations for use in naturopathy for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; nutritional supplements; chemical preparations for medical purposes for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; pharmaceutical preparations and chemico- pharmaceutical preparations for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; dietary and nutritional supplements; health food supplements for persons with special dietary requirements; chemical preparations for pharmaceutical purposes for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; pharmaceutical preparations and substances for glycemic control; pharmaceutical preparations and substances for the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; dietetic preparations and substances for glycemic control; dietetic preparations and substances for the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; dietary and nutritional supplements for glycemic control; dietary and nutritional supplements for the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; pharmaceutical preparations in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions for use in glycemic control; pharmaceutical preparations in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions for use in the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; pharmaceutical preparations and substances, dietary and nutritional substances in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions, all for use in the treatment and regulation of obesity, body weight, body fat, body composition, body weight circumference, cholesterol and LDL cholesterol levels, liver disease, steatohepatitis, infantile colic, gut microbiota, insulin levels and resistance, blood lipids, diarrhea, constipation, colitis; pharmaceutical preparations and substances, dietary and nutritional substances in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions, all for use in the treatment and regulation of intestinal injury or inflammation, Crohn's disease, cardiovascular risk factors, post bariatric surgery patients, and not including products primarily for use in the treatment of angina pectoris and high blood pressureACTIVE—
010Surgical and medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; capsulated medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; medical devices for the treatment and prevention of obesity and being overweight, and for use in weight control; medical devices for the treatment and prevention of prediabetes, diabetes and glycemic control, and for the improvement of overall metabolic health; medical devices for use in the prevention and treatment of prediabetes and diabetes; orally administered medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; surgical and medical devices, capsulated devices and orally administered medical devices all for use in the treatment and regulation of obesity, body weight, body fat, body composition, body weight circumference, cholesterol and LDL cholesterol levels, liver disease, steatohepatitis, infantile colic, gut microbiota, insulin levels and resistance, blood lipids, diarrhea, constipation, intestinal injury or inflammation, colitis, Crohn's disease, cardiovascular risk factors, post bariatric surgery patientsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Nov 20, 2023MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 20, 2023ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 15, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 14, 2023EX5GSOU EXTENSION 5 GRANTED—
Mar 14, 2023AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Mar 2, 2023EXT5SOU EXTENSION 5 FILED—
Mar 2, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 10, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 8, 2022EX4GSOU EXTENSION 4 GRANTED—
Sep 8, 2022EXT4SOU EXTENSION 4 FILED—
Sep 8, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 9, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 7, 2022EX3GSOU EXTENSION 3 GRANTED—
Feb 7, 2022EXT3SOU EXTENSION 3 FILED—
Feb 7, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 8, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 6, 2021EX2GSOU EXTENSION 2 GRANTED—
Oct 6, 2021EXT2SOU EXTENSION 2 FILED—
Oct 6, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 16, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 14, 2021EX1GSOU EXTENSION 1 GRANTED—
Apr 14, 2021EXT1SOU EXTENSION 1 FILED—
Apr 14, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 20, 2020NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Aug 25, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 25, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 5, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 20, 2020ALIEASSIGNED TO LIE—
Jul 17, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 17, 2020XAECEXAMINER'S AMENDMENT ENTERED—
Jul 17, 2020GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jul 17, 2020GNEAEXAMINERS AMENDMENT E-MAILED—
Jul 17, 2020CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 6, 2020DOCKASSIGNED TO EXAMINER—
Apr 24, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 18, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance